Latest Research, Industry, Medical and Scientific News
FDA Approves First Treatment for Frequent Urination at Night Due to Overproduction of Urine
The U.S. Food and Drug Administration today approved Noctiva (desmopressin acetate) nasal spray for adults who awaken at least two times per night to urinate due to a condition known as nocturnal polyuria (overproduction of urine during the night). Noctiva is the first FDA-approved treatment for this condition. “Today’s approval provides adults who overproduce urine at night with the first FDA-approved therapeutic option to help reduce the number of times a night they wake up to urinate,” said Hylton V. Joffe, M.D., M.M.Sc., director of the Division of Bone, Reproductive, and Urologic Products in the FDA’s Center for Drug Evaluation and Research. “It is important to know that Noctiva is not approved for all causes of night-time urination, so patients should discuss their symptoms with their health care provider who can determine the underlying cause of the night-time urination and whether Noctiva is right for them.” Read more.
Source: US FDA, March 3, 2017
HARTMANN Group to Acquire P&G Incontinence Brand in Spain/Portugal
The HARTMANN GROUP, a leading international supplier of medical and hygiene products, announced today it plans to acquire Procter & Gamble’s Lindor — one of the most well-known adult incontinence brands in the Spain and Portugal professional channel. The transaction seeks to take place by end of second quarter of fiscal year 2017 and is subject to approval by local antitrust authorities. As part of the agreement, HARTMANN is slated to obtain all P&G assets associated with the Lindor product portfolio (Lindor, Salvacamas, Lindor Care, Lindor Pants), Intellectual Property, contracts with employees, as well as a 25,000-square metre manufacturing facility in Montornés, Spain. Read more.
Source: Yahoo Finance, March 2, 2017
Third Randomized Controlled Trial (RCT) of the Vesair™ Bladder Control System For the Treatment of Stress Urinary Incontinence Delivers Promising Results
Solace Therapeutics, Inc., today announced that data from a multicenter 221 patient randomized controlled trial has met study endpoints with statistical significance. Dr. Eric Rovner will be presenting a poster of the results from the SUCCESS Clinical Trial at the Society of Urodynamics, Female Pelvic Medicine & Urogenital Reconstruction (SUFU) meeting in Scottsdale, Arizona on Thursday, March, 2nd. This is the Company’s third randomized controlled trial to evaluate the safety and efficacy of the Vesair Bladder Control System; a novel, office-based, reversible treatment designed to reduce or eliminate urine leakage in female patients with Stress Urinary Incontinence (SUI). Read more.
Source: Business Wire, March 1, 2017
NMC Urged to Tackle ‘Glaring Hole’ in Bowel and Bladder Education
Source: Nursing Times, March 1, 2017
Pelvic Floor Symptoms May Lead To Exercise Avoidance in Menopausal Women
Physical activity improves health and may delay the onset of chronic diseases. For women in particular, the rate of some chronic diseases accelerates at middle age around the time of menopause; therefore it is important to identify the determinants of health-enhancing physical activity during midlife in this population. The main aim of this study was to characterize the level of physical activity and to examine the association between different female reproductive factors and objectively-measured physical activity in middle-aged women. The reproductive factors included cumulative reproductive history index, and perceived menopausal and pelvic floor dysfunction symptoms. Read more.
Source: MedicalResearch.com, Feburary 28, 2017
Hatch Medical to Broker Innovative Male Urinary Incontinence Device
Hatch Medical, L.L.C., a medical device incubator and technology brokerage firm, announced today that it has entered into an agreement with MUCOM, L.L.C. to broker the sale or license of its patented male urinary incontinence device MUI Comfort™. MUI Comfort™ is an integrated external collection system that meets the needs of a growing demographic that is coping with the consequences of stress, urge, and overflow incontinence. This innovative technology is differentiated from competing products by providing a complete solution that addresses both functional and psychological aspects associated with male urinary incontinence. Read more.
Source: Yahoo Finance! February 16, 2017